Amylocaine

Amylocaine

SCHEMBL81361

CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 1.00
CYP1A2 P05177 1/20 1.00
CYP2C19 P33261 1/20 1.00
TDP1 Q9NUW8 4/20 0.44
TSHR P16473 3/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 1/20 0.44
HTR1A P08908 1/20 0.41
SCN1A P35498 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN3A Q9NY46 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41
F2 P00734 1/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amylocaine SCHEMBL81360 1.00 CYP2D6 (1.00) CYP2D6CYP1A2CYP2C19TDP1TSHR
Amylocaine SCHEMBL25684 0.98 CYP2D6 (0.97) CYP2D6CYP1A2CYP2C19TDP1TSHR
Amylocaine SCHEMBL25686 0.98 CYP2D6 (0.97) CYP2D6CYP1A2CYP2C19TDP1TSHR
Amylocaine SCHEMBL1648490 0.97 CYP2D6 (0.94) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL13514895 0.87 CYP2D6 (0.76) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL1783308 0.83 CYP2D6 (0.71) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL29351583 0.83 CYP2D6 (0.70) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL27692599 0.82 CYP2D6 (0.69) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL28684600 0.82 CYP2D6 (0.69) CYP2D6CYP1A2CYP2C19TDP1TSHR
SCHEMBL4576579 0.79 CYP2D6 (0.66) CYP2D6CYP1A2CYP2C19TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1988 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144801-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-05-28 US claimed
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT UNIV KOREA RES & BUS FOUND (KR) 2026-04-30 US claimed
EP-4436552-B1 GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC OREXA B V (NL) 2026-02-04 EP claimed
WO-2025235864-A1 COATED NEEDLE ADMINISTRATION SYSTEMS EVOLUS, INC. (US) 2025-11-13 WO claimed
US-20250332183-A1 COMPOSITIONS AND METHODS FOR THE STIMULATION OF INTERMEDIATE MACROPHAGES AND TREATMENTS THEREWITH AYUVIS RESEARCH, INC. 2025-10-30 US claimed
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-16 US claimed
EP-4578441-A1 TREATMENT OF LOCALIZED PAIN PlantTec Medical GmbH (DE) 2025-07-02 EP claimed
US-20250205278-A1 METHODS AND COMPOSITIONS FOR WOUND HEALING ABBOTT NICHOLAS L (US) 2025-06-26 US claimed
WO-2025128639-A1 HYDROGELS COMPRISING PROTEIN-STABILIZED NANOPARTICLES FOR EXTENDED RELEASE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-19 WO claimed
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics BIOPOLIMERI S.R.L. (IT) 2025-06-17 US claimed
EP-0999839-B1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES LEVIN BRUCE H (US) 2004-06-23 EP claimed
US-20030027833-A1 Compositions and delivery systems for administration of a local anesthetic agent CORIUM INTERNATIONAL, INC. 2003-02-06 US claimed
WO-2002089849-A1 COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT CORIUM INTERNATIONAL (US) 2002-11-14 WO claimed
US-6432986-B2 INTRANOSALLY ADMINISTERING OF ANESTHETICS BHL PATENT HOLDINGS LLC 2002-08-13 US claimed
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES BHL PATENT HOLDINGS LLC 2001-12-27 US claimed
US-6297290-B2 INTENDED TO ANESTHETIZE THE SKIN OR THE MUCOUS MEMBRANES OR TO TREAT PRURITUS. CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 2001-10-02 US claimed
WO-2001043733-A2 COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION LEVIN BRUCE H (US) 2001-06-21 WO claimed
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation LEVIN BRUCE H (US) 2001-06-21 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES TNNC1, KIT, PDE3A CYP2D6 2876/4885CYP1A2 2135/4885CYP2C19 906/4885
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics CD44, HCAR3, HCAR2 CYP2D6 1977/4885CYP1A2 1332/4885CYP2C19 434/4885
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation CXCR5, CCL5, C5AR2 CYP2D6 2490/4885CYP1A2 1652/4885CYP2C19 970/4885
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT CES2, DAGLA, ACHE CYP2D6 71/4885CYP1A2 1231/4885CYP2C19 272/4885
US-20250332183-A1 COMPOSITIONS AND METHODS FOR THE STIMULATION OF INTERMEDIATE MACROPHAGES AND TREATMENTS THEREWITH CD14, MYADM, MYD88 CYP2D6 3653/4885CYP1A2 2512/4885CYP2C19 3644/4885
US-20260144801-A1 COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS CPT1B, HPGD, PTGES CYP2D6 756/4885CYP1A2 360/4885CYP2C19 571/4885
US-20250319025-A9 COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF PHOSPHO1, SGMS1, LIPA CYP2D6 2874/4885CYP1A2 2988/4885CYP2C19 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.